On the Radar: Five high-value biotech stocks

Our new On the Radar report returns with fresh insights from Simos Simeonidis, PhD, Rodman & Renshaw's senior biotech analyst, who highlights biotech stocks which he believes will be good value

Epizyme Achieves Lead Candidate Milestone for Third Target in GSK Collaboration, Receives $4 Million in Milestone and License Payments

- Potential Therapeutic Candidates Now Identified for All Three GSK Collaboration Targets - CAMBRIDGE, Mass., April 22, 2014 /PRNewswire/ -- Epizyme, Inc. EPZM +15.39% , a clinical stage...

Avalanche Biotechnologies Secures $55 Million in Oversubscribed Series B Financing

- Proceeds will Further Strengthen Avalanche's Proprietary BioFactoryTM Platform and Advance Clinical Program in Wet Age-Related Macular Degeneration - MENLO PARK, Calif., April 22, 2014...

GSK, Theravance launch PhIII trial; ContraFect files $23M IPO for infectious disease R&D;

@FierceBiotech: AbbVie heads to the FDA with its hep C combo in a race with Gilead, Merck. More | Follow @FierceBiotech @JohnCFierce: GSK punts programs and rights on cancer to Novartis. MAGE-A3 a...

Epizyme jumps on $4M payday

Shares of Cambridge, MA-based Epizyme jumped 10% this morning after the company announced that it had won a $4 million payment from GSK after hitting the third of the three histone methyltransferase targets in their collaboration.

Principia Biopharma Secures $50 Million Series B Financing

Proceeds enable expansion into a clinical stage company April 22, 2014 08:30 AM Eastern Daylight Time SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Principia Biopharma Inc. today announced that it...

ProNAi Therapeutics Raises $59.5 Million Series D Financing

Proceeds Will Advance Clinical Studies of Its BCL2 Targeted Cancer Drug and Other Pipeline Candidates April 21, 2014 PLYMOUTH, MICH. — ProNAi Therapeutics, Inc., a developer of novel nucleic...

VC groups put up $165M for a trifecta of biotech rounds

A Detroit-based biotech has landed a $59.5 million round to continue its work on a nucleic acid-based DNAi cancer therapy now in a mid-stage trial. ProNAi Therapeutics CEO Mina Sooch says that's enough cash to get the company through 2016, with plans to pursue partnership talks as well as a discussion with the FDA about potential ways to accelerate the approval process for their lead therapy.

AbbVie heads to the FDA with its hep C combo in a race with Gilead, Merck

AbbVie has submitted an FDA application for its promising all-oral hepatitis C treatment, expecting approval this year as it prepares for a three-way race with perceived leaders Gilead Sciences and Merck.

ENANTA PHARMACEUTICALS ANNOUNCES NEW DRUG APPLICATION SUBMISSION TO THE U.S. FDA FOR ALL-ORAL, INTERFERON-FREE HEPATITIS C REGIMEN

AbbVie's submission to FDA triggers $20 million milestone payment to Enanta Regimen includes Enanta's and AbbVie's protease inhibitor ABT-450 WATERTOWN, Mass.--Apr. 22, 2014-- Enanta...